Home > Products > Antibodies > Biosimilars

Research Grade Pasotuxizumab (HC669016)

Price(USD): $
Spec:
  • 100ug
  • 1mg
Number:
Contact us
  • Overview
  • Images
  • References
  • Datasheet
Overview
Catalog No.HC669016
Species reactivityHuman
ApplicationsResearch Grade Biosimilar
Host speciesHumanized
Isotype(scFv-heavy-kappa)-(scFv-heavy-lambda)
Expression systemMammalian Cells
ClonalityMonoclonal
TargetNAALAD1, Prostate-specific membrane antigen, NAALADase I, PSMA, PSM, Pteroylpoly-gamma-glutamate carboxypeptidase, Glutamate carboxypeptidase 2, N-acetylated-alpha-linked acidic dipeptidase I, Glutamate carboxypeptidase II, FOLH1, FGCP, FOLH, Folylpoly-gamma-glutamate carboxypeptidase, Folate hydrolase 1, GCPII, Membrane glutamate carboxypeptidase, Cell growth-inhibiting gene 27 protein, mGCP, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Concentration1mg/ml
Endotoxin levelPlease contact the lab for this information.
Purity>95% purity as determined by SDS-PAGE.
PurificationPurified by nickel column chromatography.
AccessionQ04609 & P07766
FormLiquid
Storage buffer0.01M PBS,pH7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -380°C.
Alternate NamesBispecific,BAY2010112,BITEMT112,MT-112,CAS:1442657-12-6
BackgroundPasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).
NoteFor research use only. Not for use in clinical or therapeutic applications.
Images
  • Bioactivity

    Detects CD3E in indirect ELISAs.

References

Recommendation